03-02-2025 | IL-23 Inhibitor | Research Letter
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study
Authors:
Siddhartha Sood, Alexander Rimke, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Alim R. Devani, Ronald Vender, Jensen Yeung, Vimal H. Prajapati
Published in:
American Journal of Clinical Dermatology
Login to get access
Excerpt
In routine clinical practice, biologic switching is common in adult patients with plaque psoriasis [
1]. While our group previously reported overall real-world 16-week and 52-week treatment outcomes of bimekizumab, a novel interleukin (IL)-17A/IL-17F inhibitor, limited information exists on switching class from an IL-23 inhibitor (IL-23i) to bimekizumab [
2,
3]. This subset analysis of our retrospective cohort study specifically analyzes bimekizumab use following IL-23i exposure. …